|Systematic (IUPAC) name|
|Biological half-life||12.5 hours|
|Molar mass||410.42 g/mol|
|(what is this?)|
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|